To measure aqueous flare levels in treatment naïve eyes suffering from wet age- related macular degeneration (wAMD) treated with intravitreal brolucizumab.
Methods
Patients with treatment naïve wAMD in one eye were prospectively enrolled. Flare levels were measured with laser flare photometry at baseline, 1 day and 1 month after each of the 3 monthly injections during the loading phase.
Results
Twenty-two eyes from 22 patients aged 76.7 ± 6.0 years were enrolled. Flare values were 10.6 ± 3.7 photons/msec at baseline and 12.6 ± 5.8 photons/msec at the last follow up visit, 1 month after the third injection (p = 0.289, repeated measures ANOVA). The mean change in flare after the first injection was 4.2 ± 3.6. photons/msec, 6.6 ± 8.9 photons/msec after the 2nd and 8.6 ± 20.8 photons/msec after the 3rd injection (p = 0.640, repeated measures ANOVA). No patient had clinical signs of intraocular inflammation.
Conclusions
Eyes receiving brolucizumab injections for wAMD showed similar flare at baseline, during and 1 month after completion of three-monthly intravitreal injections. There was no evidence of subclinical inflammation during the loading phase of brolucizumab based on laser flare photometry measurements.
NguyenQDDasADoDV, et al.Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology2020; 127: 963–976.
6.
DugelPUSinghRPKohA, et al.HAWK and HARRIER. Ophthalmology2021; 128: 89–99.
7.
AgostiniHMulyukovZTsilimbarisM, et al.Comparison of the efficacy of brolucizumab with natural disease progression in wet AMD using clinical data from the phase III HAWK and HARRIER trials and modelled placebo data. Curr Eye Res2020; 45: 1298–1301.
8.
BaumalCRSpaideRFVajzovicL, et al.Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology2020; 127: 1345–1359.
9.
AndersonWJDa CruzNFSLimaLH, et al.Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitr2021; 7: 37.
10.
LadasJGWheelerNCMorhunPJ, et al.Laser flare-cell photometry: methodology and clinical applications. Surv Ophthalmol2005; 50: 27–47.
11.
SawaMTsurimakiYTsuruT,et al.New quantitative method to determine protein concentration and cell number in aqueous in vivo. Jpn J Ophthalmol1988; 32: 132–142.
12.
DemirelSBiliciSBatıoğluF,et al.Is there any difference between ranibizumab and aflibercept injections in terms of inflammation measured with anterior chamber flare levels in age-related macular degeneration patients: a comparative study. Ophthalmic Res2016; 56: 35–40.
13.
SaddaSRHolzFGStaurenghiG, et al.The importance of imaging to identify early signs of intraocular inflammation expert opinion for brolucizumab. Ophthalmologica2022; 245: 588–591.
14.
MonésJSrivastavaSKJaffeGJ, et al.Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab. Ophthalmology2021; 128: 1050–1059.
15.
HiranoTKumazakiATomiharaR, et al.Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Sci Rep2023; 13: 10901.
16.
BlahaGRBrooksNOMackelCE, et al.Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications. Retina2015; 35: 577–581.
17.
Dolar-SzczasnyJBucoloCZweifelS, et al.Evaluation of aqueous flare intensity in eyes undergoing intravitreal bevacizumab therapy to treat neovascular age-related macular degeneration. Front Pharmacol2021; 12: 656774.
18.
HautamäkiALuomaAImmonenI. Anterior chamber flare during bevacizumab treatment in eyes with exudative age-related macular degeneration. Retina2016; 36: 2183–2190.
19.
KissCMichelsSPragerF, et al.Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina2006; 26: 877–881.
20.
UzunAYalcindagFNDemirelS, et al.Evaluation of aqueous flare levels following intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ocul Immunol Inflamm2017; 25: 229–232.
21.
YeniadBAyranciOTuncerS, et al.Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases. Eur J Ophthalmol2011; 21: 156–161.
22.
MoriokaMTakamuraYYamadaY, et al.Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol2018; 256: 2301–2307.
23.
ShirayaTKureKArakiF, et al.Correlation between anterior chamber flare changes and diabetic macular edema after intravitreal injection of ranibizumab and aflibercept. Jpn J Ophthalmol2020; 64: 250–256.
24.
NomaHMimuraTYasudaK,et al.Functional–morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab. Br J Ophthalmol2017; 101: 180–185.
25.
HiranoTToriyamaYTakahashiY, et al.Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema. Am J Ophthalmol Case Rep2023; 29: 101788.
26.
SaitoMKoboriHNozukiN, et al.A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer. Am J Ophthalmol Case Rep2022; 28: 101727.
27.
KubotaT. Aqueous flare in eyes with age-related macular degeneration. Jpn J Ophthalmol1994; 38: 67–70.
28.
HautamäkiALuomaAImmonenI. Anterior chamber flare during bevacizumab treatment in eyes with exudative age-related macular degeneration. Retina2016; 36: 2183–2190.
29.
FreddoTF. A contemporary concept of the blood-aqueous barrier. Prog Retin Eye Res2013; 32: 181–195.
30.
Patil NikhilS. Risk of intraocular inflammation after injection of antivascular endothelial growth factor agents: a meta-analysis. Retina2022; 42: 2134–2142.
31.
IyerPGPedenMCSuñerIJ, et al.Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep2020; 20: 100989.
32.
SharmaAKumarNParachuriN, et al.Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye2021; 35: 1292–1294.
33.
TeraoRObataROkuboA, et al.Cytokine profiles in the aqueous humor following brolucizumab administration for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol2023; 261: 2465–2476.
34.
MukaiRMatsumotoHAkiyamaH. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLOS ONE2021; 16: e0259879.
